SEATTLE, Oct. 31, 2023 /PRNewswire/ -- HDT Bio Corp., a clinical-stage private company developing advanced RNA products to treat and prevent infectious diseases and cancer, today announced that Dr. Steven Reed, Chief Executive Officer of HDT Bio, will present at the...

Award will fund the development of HDT-201, HDT Bio's thermo-stable and broad-spectrum intranasal RIG-I Agonist RNA SARS-CoV-2 antiviral candidate HDT-201 investigated as pre-exposure or post exposure prophylactic in high-risk situations SEATTLE, Oct. 4, 2023...

Scientific Advisors to provide expertise and counsel on the clinical development of its RNA-based oncology pipeline candidates HDT Bio announces esteemed medical experts Dr. Charles Cobbs of the Swedish Neuroscience Institute and Dr. Elizabeth Jaffee of Johns Hopkins...

LION™-formulated repRNA vaccination exhibited a significant safety profile, along with enhanced efficacy and biodistribution response when compared to lipid nanoparticle (LNP)-formulated repRNA vaccines in mice Study findings, published in the peer-reviewed...

LION-formulated, repRNA vaccination against HIV-1 and ZIKV successfully produced a robust immunological response in pregnant rabbits; maternal antibodies were transferred in utero to newborn kits Findings published in the peer-reviewed journal Molecular Therapy...